Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab in Adult and Adolescent Patients with aHUS
2023-505089-27-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of crovalimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Roche. Primary endpoint: Proportion of patients with complete TMA response (cTMAr). Planned start Jul 2021; status: authorised.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2023-505089-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505089-27-00.